Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab.

Aditi Khandelwal Julie K Wright Katerina Pavenski Linda R Taggart

CMAJ

PGY-4, Adult Hematology (Khandelwal), Department of Internal Medicine; Division of Infectious Diseases and the Eliot Phillipson Clinician-Scientist Training Program (Wright), Department of Medicine, University of Toronto; Division of Transfusion Medicine (Pavenski), Department of Laboratory Medicine; Division of Infectious Diseases (Taggart), Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ont.

Published: December 2017

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738249	PMC
http://dx.doi.org/10.1503/cmaj.170508	DOI Listing

Publication Analysis

Top Keywords

risks novel

novel therapeutics

therapeutics gonococcemia

gonococcemia immune-suppressed

immune-suppressed patient

patient receiving

receiving eculizumab

risks

therapeutics

gonococcemia

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!